Click here for printer friendly page
Abingworth closes new life sciences venture fund on £300m31/01/2007. Source: AltAssets. 
 Abingworth has closed its eighth life sciences fund, Abingworth Bioventures V, on £300m. The fund's target was £250m. It held a first closing on £222m on 21 December 2006.
ABV V will invest in biotechnology and medical companies, both in Europe and in the US. The fund will invest across the life sciences field in technologies, therapeutics and medical devices at all stages of development from early stage private deals to quoted companies. ABV V plans to make more than 20 venture investments.
Abingworth has funds under management of over $1.25bn and offices in London, Cambridge (UK), Menlo Park and Boston.
The firm's investments have included Alnylam Pharmaceuticals, Aurora Biosciences, Aviron, GelTex Pharmaceuticals, Gilead Sciences, Healtheon, IDEC Pharmaceuticals, Pharmion, PowderMed and Solexa.
Copyright © 2007 AltAssets
|
